--- title: "韓國的醫療保健熱潮催生了新的億萬富翁" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/283206608.md" description: "韓國的醫療保健行業正在蓬勃發展，製藥公司追求豐厚的合作伙伴關係，創造了新的億萬富翁。三春堂製藥的尹大仁以 59 億美元的淨資產位列全國富豪榜第十，得益於與第一三共達成的一項減肥產品交易。新晉億萬富翁包括 ABL Bio 的李相勳（14 億美元）和 Voronoi 的金炫泰（13 億美元）。醫療保健財富的崛起反映了向先進研發的轉變，韓國公司與全球企業簽署了更多的聯合研究協議，標誌着行業的重大轉型" datetime: "2026-04-18T01:57:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283206608.md) - [en](https://longbridge.com/en/news/283206608.md) - [zh-HK](https://longbridge.com/zh-HK/news/283206608.md) --- # 韓國的醫療保健熱潮催生了新的億萬富翁 Yoon Dae-in, chairman of Sam Chun Dang Pharm, joined the ranks of the nation’s 50 richest this year at the 10th place after his company struck a deal to develop a weight-loss product. Dae-in, with a net worth of $5.9 billion, has now surpassed many tech and media tycoons in wealth following the company’s agreement with Japan’s Daiichi Sankyo signed in January to develop a pill that works similarly to the weight-loss injectable Wegovy made by Denmark-based Novo Nordisk, according to U.S. magazine _Forbes_. Two additional pharmaceutical entrepreneurs have entered the rankings for the first time. One of them is biologist Lee Sang-hoon with a net worth of $1.4 billion, ranking 39th in the country. He is the chairman and CEO of ABL Bio, which develops antibodies to improve treatment outcomes for cancer and neurodegenerative diseases. Lee Sang-hoon, chairman and CEO of ABL Bio. Photo courtesy of the company It signed a $2.6 billion technology-transfer deal with U.S.-based pharma company Eli Lilly in November last year. Another new billionaire is Hyuntae Kim (with a net worth of $1.3 billion), CEO of Voronoi, which is known for its AI-powered drug discovery platform and has two prospective cancer treatments in development. These newly created fortunes underscore the growing prominence of South Korea’s healthcare sector, and more specifically biotech, as a pathway to wealth in a country long dominated by industries such as electronics, semiconductors and online gaming. Six of the country’s 50 richest are in the healthcare industry, with one of them, Seo Jung-jin, claiming the third place with $8.1 billion in net worth. Ho-Cheol Lee, senior analyst at Shinhan Securities, building credibility with global pharmaceutical leaders has been central to the sector’s rise. Over the past year, Korean firms have signed more than a dozen joint research agreements with multinational companies, up from seven in 2024. "This marks a dramatic acceleration," he told _Forbes_. "Until 2023, the sector averaged fewer than three such deals annually." The increasing global profile of South Korea’s pharmaceutical players reflects a broader transition from domestic manufacturing to advanced research and development, according to Lee. This shift, he says, has been driven by "several pioneer companies that successfully secured multibillion dollar licensing deals with Big Pharma." Among these trailblazers are Jung-jin, co-founder of cancer-treating drugs producer Celltrion and Park Soon-jae ($2.6 billion in net worth), founder of Alteogen. The latter secured a $450 million licensing agreement with Merck in 2024 for a cancer therapy, sending its shares higher and earning Park a debut on the country’s rich list that year. "These milestones proved that Korean biotech could move beyond domestic production to high-stakes research and development," says Lee. ### 相關股票 - [4568.JP](https://longbridge.com/zh-HK/quote/4568.JP.md) - [NVO.US](https://longbridge.com/zh-HK/quote/NVO.US.md) - [LLY.US](https://longbridge.com/zh-HK/quote/LLY.US.md) - [MRK.US](https://longbridge.com/zh-HK/quote/MRK.US.md) - [SHG.US](https://longbridge.com/zh-HK/quote/SHG.US.md) - [DSNKY.US](https://longbridge.com/zh-HK/quote/DSNKY.US.md) ## 相關資訊與研究 - [三得利將以 12 億美元收購第一三共非處方藥部門——日經報導](https://longbridge.com/zh-HK/news/282791025.md) - [美國 FDA 測試即時取得臨牀試驗資料，以利加速藥物審核](https://longbridge.com/zh-HK/news/286686699.md) - [減肥神藥與華盛頓的權力迴廊｜藍血工廠](https://longbridge.com/zh-HK/news/286663213.md) - [新加坡康橋資本與 GHO 合併 組成全球最大醫療保健投資管理平台 | 聯合早報網](https://longbridge.com/zh-HK/news/287080690.md) - [百濟神州，製藥界的 “新物種”](https://longbridge.com/zh-HK/news/286376124.md)